Previous 10 | Next 10 |
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that the Company approved the grant of equity awards to two new employees with a grant date of August 16, 2021, as equity indu...
XtalPi, a US-China AI-based drug discovery company, completed a $400 million Series D financing at an estimated valuation of $2 billion. Shanghai's HutchMed announced a $310 million deal to acquire greater China rights to Epizyme's epigenetic treatment for niche cancers. Advaccine...
Image source: The Motley Fool. Epizyme, inc (NASDAQ: EPZM) Q2 2021 Earnings Call Aug 9, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Epizyme, inc (EPZM) Q2 2021 Earnings Call Transcript
On Monday, Epizyme (NASDAQ: EPZM) shares were hit with the one-two punch of an earnings miss and a major change in leadership. In late afternoon trading, the stock of the cancer drug specialist was down by nearly 10%. Epizyme released its second-quarter results on Monday morning...
Epizyme, Inc. (EPZM) Q2 2021 Earnings Conference Call August 09, 2021 08:30 AM ET Company Participants Craig West - Vice President, Investor Relations Rob Bazemore - President & Chief Executive Officer Grant Bogle - Incoming President & Chief Executive Officer Shefali Agarwal - Execut...
Current Chief Executive Officer, Robert Bazemore, to Step Down; Current Board Member, Grant Bogle, Named Incoming CEO Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies today announced...
Total Revenue of $13.0 Million in 2Q 2021; TAZVERIK ® Net Product Revenues of $8.0 Million Revised Commercial Strategy and Operating Plan to Accelerate Adoption of TAZVERIK ® and Focus Investment on Important Value-Driving Programs IND Clearance for N...
Hutchmed (NASDAQ:HCM) has collaborated with Epizyme (NASDAQ:EPZM) to research, develop, manufacture and commercialize TAZVERIK in Greater China, including mainland China, Hong Kong, Macau and Taiwan (the Territory). TAZVERIK is a methyltransferase inhibitor of EZH2 developed by Epiz...
Collaboration designed to accelerate global development and investigate TAZVERIK ® combinations with HUTCHMED’s novel oncology medicines portfolio Epizyme to receive US$25 million upfront payment and up to US$285 million in potential milestone payments, togethe...
News, Short Squeeze, Breakout and More Instantly...
TAZVERIK® (tazemetostat) Net Product Revenue of $11.0 Million for 2Q 2022; Total End User Demand Grew 17% vs. 1Q 2022 First Patient Dosed in the SET-101 Phase 1/1b Study of EZM0414, the Company’s Novel, First-in-Class, Oral SETD2 Inhibitor Merger with I...
The biotech investment sector has always been its own market, very distinct from other sectors. So it was no surprise that when most sectors turned slowly upward after the pandemic-inspired crash, Biotech (XBI) rose 164%, exceeding the overall market (SPY) performance by triple digits. Then, a...
Shares of the commercial-stage cancer company Epizyme (NASDAQ: EPZM) are soaring today. Specifically, the drugmaker's stock is up by a handsome 58% as of 10:50 a.m. ET Monday. Epizyme's shares are racing higher today in response to a buyout agreement with French biopharma Ipse...